

CYTOKINETICS INC  
Form 8-K  
June 29, 2006

**Table of Contents**

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, DC 20549  
FORM 8-K**

**CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934  
Date of Report (Date of earliest event reported): June 29, 2006**

**CYTOKINETICS, INCORPORATED**  
(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction  
of incorporation)

**000-50633**  
(Commission File Number)

**94-3291317**  
(IRS Employer  
Identification No.)

**280 East Grand Avenue  
South San Francisco, California 94080**  
(Address of principal executive offices, including zip code)  
**(650) 624-3000**  
(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**TABLE OF CONTENTS**

ITEM 8.01. OTHER EVENTS.

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.

SIGNATURES

EXHIBIT 99.1

---

**Table of Contents**

**ITEM 8.01. OTHER EVENTS.**

Cytokinetics, Incorporated (the Company ) issued a press release and will hold a conference call and webcast in connection with the announcement of results from a Phase I clinical trial of its drug candidate, CK-1827452, a novel cardiac myosin activator, administered intravenously. The clinical trial was designed as a double-blind, randomized, placebo-controlled, dose-escalation trial conducted to investigate the safety, tolerability, pharmacokinetics and pharmacodynamic profile of a six-hour infusion of CK-1827452 in healthy volunteers. Data from the Phase I clinical trial of CK-1827452 will be presented at the 10<sup>th</sup> Annual Meeting of the Heart Failure Society of America on Wednesday, September 13, 2006 in Seattle, Washington. A copy of the press release is being filed with this Current Report on Form 8-K as Exhibit 99.1, and is hereby incorporated by reference under this Item 8.01. The press release contains information regarding access to the conference call and webcast concerning the subject matter of the release, which is scheduled to take place at 10:30 AM (Eastern Time) on June 29, 2006.

**ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.**

**(c) Exhibits.**

The following Exhibit is filed as part of this Current Report on Form 8-K:

<b>Exhibit No.</b>	<b>Description</b>
99.1	Clinical Trial Announcement Press Release, dated June 29, 2006.

**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**CYTOKINETICS, INCORPORATED**

By: /s/ Sharon Surrey-Barbari  
Sharon Surrey-Barbari  
*Senior Vice President, Finance and Chief Financial  
Officer*

Dated: June 29, 2006